Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics
Myelodysplastic syndromes (MDS), clonal hematopoietic stem-cell disorders mainly affecting older adult patients, show ineffective hematopoiesis in one or more of the lineages of the bone marrow. A number of MDS progresses to acute myeloid leukemia (AML) with the involvement of genetic and epigenetic mechanisms affecting PI-PLC β1. The molecular mechanisms underlying the MDS evolution to AML are still unclear, even though it is now clear that the nuclear signaling elicited by PI-PLC β1, Cyclin D3, and Akt plays an important role in the control of the balance between cell cycle progression and apoptosis in both normal and pathologic conditions. Moreover, a correlation between other PI-PLCs, such as PI-PLC β3, kinases and phosphatases has been postulated in MDS pathogenesis. Here, we review the findings hinting at the role of nuclear lipid signaling pathways in MDS, which could become promising therapeutic targets.
KeywordsAcute Myeloid Leukemia JAK2 V617F47 International Prognostic Scoring System DNMT Inhibitor Epigenetic Therapy
This work was supported by Italian MIUR-FIRB (Human Proteome Net and Accordi di Programma 2010), Italian MIUR PRIN and Celgene Corp.